Preferred Label : Mutant-selective EGFR Inhibitor JIN-A02;
NCIt synonyms : EGFR TKI BPI-361175; EGFR Inhibitor JIN-A02;
NCIt definition : An orally bioavailable, mutant-selective, fourth-generation epidermal growth factor
receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration,
mutant-selective EGFR inhibitor JIN-A02 targets, binds to, and inhibits the activity
of certain EGFR mutations, specifically double and triple mutations containing C797S
mutations, including the double mutations Ex19Del/C797S and L858R/C797S, and the Ex19Del/T790M/C797S
triple mutation. This prevents EGFR-mediated signaling in cancer cells harboring these
mutations. This may result in the inhibition of proliferation in EGFR-expressing tumors
cells. EGFR, a receptor tyrosine kinase that plays a major role in tumor cell proliferation,
is often overexpressed or mutated in cancer cells.;
Molecule name : JIN A02; JIN-A02;
NCI Metathesaurus CUI : CL1793057;
Origin ID : C188241;
UMLS CUI : C5706471;
Semantic type(s)
- concept_is_in_subset
- has_target
